ARTICLES BY LOUIS
Equipment You Need At Your Cell-And-Gene CDMO
What equipment is essential at the CDMO assisting with your cell and gene therapy development and production? I’ve received some details via an investigation into Harvard’s Center for Advanced Biological Innovation and Manufacturing, and a discussion with the CEO & President of GE Healthcare Life Sciences.
A Harvard Assist For Cell And Gene Bottlenecks
Bottlenecks and backlogs in development and production of cell and gene therapies. Harvard to the rescue. Actually, Harvard with partners, such as companies familiar to Outsourced Pharma readers. But what will go into the the $50 million Center for Advanced Biological Innovation and Manufacturing? We’ve got exclusive details.
Biopharma Outsourcing: Propelling Productivity Past 2020
Stanley Crooke, M.D., Ph.D., founder, chairman, and CEO, Ionis Pharmaceuticals, proclaims: “Biotech has done a wonderful job of convincing Big Pharma to outsource.” James Mackay, Ph.D., founder, president, and CEO, Aristea Therapeutics, says: "Don’t call CDMOs 'service providers.'” Both CEOs are focused on biotech productivity.
Biotech Music In The "Twenty-Twenties"
Welcome to the melodious-sounding “Twenty-Twenties.” What correspondingly pleasant harmonies will we hear from our drug industry during the second decade of this millennium? James Mackay, Ph.D., founder, president, and CEO, Aristea Therapeutics, and Stanley Crooke, M.D., Ph.D., founder, chairman, and CEO, Ionis Pharmaceuticals, predict a virtuosity emanating from the halls of biotech.
Outsourcing Industry: Naughty Or Nice in 2019?
It appears we never grow too old for a visit from the North Pole. “So, Louis,” a well-rounded Santa Claus in red dress and cheeks says through an unsettling wry smile. “Has your drug development and manufacturing outsourcing sector been good this year?” Here’s how I replied …
GSK And Others Panning For “New Gold” In Blockchain River
“We're keen to get complete access, and full visibility, to our supply chain. This will in fact give us that desired end-to-end supply-chain transparency. It will improve the quality of so many of our decisions,” says Barry Moore, Head of Clinical Supply Chain Solutions for GSK, and Chairman of the Clinical Supply Blockchain Working Group (CSBWG)
Message To Senator Warren From CDMOs: Rethink Education
It’s been a season of discontent over political plans for drug pricing, health care, and the biopharma industry. However, a CEO of a CDMO isn’t thinking particularly about pharma- and healthcare-related proposals. It’s education that’s on his mind — and finding skilled workers locally.
Farm To Pharma: Outsourcing Lessons From Back Home
Growing up on a farm in Idaho, Marty Hughes of Cidara Therapeutics learned this about quality: If you can afford old equipment, you can afford new equipment. Here’s what he means, and some other of his down-home aphorisms to improve your outsourcing activities.
Congressional Testimony: Stop Targeting U.S.-Based API Manufacturers
A representative for U.S.-based CDMOs recently testified before Congress regarding the fact 80% of our API is manufactured overseas. If you ask me, they picked the right guy to hear from. Here’s some “supplemental testimony” you’ll want to hear from Edward Price, President & CEO, SEQENS N.A.
Women In Our Workforce: A Biogen Millennial Manages CMOs
Tara Caiano, Virtual Plant Manager, Biogen is a young-woman professional. We featured her a few weeks ago, just after she had relocated from Biogen’s Boston location to manage an external supply-chain partner in Switzerland. She also spoke to me about some of her personal experiences.